BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 21, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GDC-0980: Phase I data

In an ongoing, open-label, dose-escalation Phase I trial in 12 evaluable patients, GDC-0980 was well tolerated at doses up to 16 mg/day. Additionally, 1 cycle of 8 mg once-daily GDC-0980 led to a 32% decrease...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >